Hepatocellular carcinoma: Clinical frontiers and perspectives

Jordi Bruix, Gregory James Gores, Vincenzo Mazzaferro

Research output: Contribution to journalArticle

722 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death and is currently the main event leading to death in patients with cirrhosis. Evolving information suggests that the metabolic syndrome with non-alcoholic liver disease may be an important cause of HCC in addition to viral hepatitis and alcohol-induced liver disease. The molecular pathogenesis is extremely complex and heterogeneous. To date the molecular information has not impacted on treatment decisions. Periodic surveillance imaging of patients with cirrhosis is widely practiced, especially because diagnostic, radiographic criteria for early-stage HCC have been defined (including nodules between 1 and 2 cm) and effective treatment is available for tumours detected at an early stage. Worldwide the approach to resection versus transplantation varies depending upon local resources, expertise and donor availability. The criteria for transplantation are discussed, and the controversial areas highlighted with evidence-based recommendations provided. Several approaches are available for intermediate stage disease, including radiofrequency ablation, transarterial chemoembolisation and radioembolisation; the rationale for these therapies is buttressed by appropriate outcome-based studies. For advanced disease, systemic therapy with sorafenib remains the option best supported by current data. Thus, while several trials have failed to improve the benefits of established therapies, studies assessing the sequential or combined application of those already known to be beneficial are needed. Also, new concepts are provided in regards to selecting and stratifying patients for second-line studies, which may help explain the failure of prior studies.

Original languageEnglish (US)
Pages (from-to)844-855
Number of pages12
JournalGut
Volume63
Issue number5
DOIs
StatePublished - May 1 2014

Fingerprint

Hepatocellular Carcinoma
Liver Diseases
Fibrosis
Transplantation
Therapeutics
Hepatitis
Neoplasms
Alcohols
Outcome Assessment (Health Care)
Tissue Donors

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatocellular carcinoma : Clinical frontiers and perspectives. / Bruix, Jordi; Gores, Gregory James; Mazzaferro, Vincenzo.

In: Gut, Vol. 63, No. 5, 01.05.2014, p. 844-855.

Research output: Contribution to journalArticle

Bruix, Jordi ; Gores, Gregory James ; Mazzaferro, Vincenzo. / Hepatocellular carcinoma : Clinical frontiers and perspectives. In: Gut. 2014 ; Vol. 63, No. 5. pp. 844-855.
@article{980b284bb5db4b14aa1a219f0a32ea62,
title = "Hepatocellular carcinoma: Clinical frontiers and perspectives",
abstract = "Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death and is currently the main event leading to death in patients with cirrhosis. Evolving information suggests that the metabolic syndrome with non-alcoholic liver disease may be an important cause of HCC in addition to viral hepatitis and alcohol-induced liver disease. The molecular pathogenesis is extremely complex and heterogeneous. To date the molecular information has not impacted on treatment decisions. Periodic surveillance imaging of patients with cirrhosis is widely practiced, especially because diagnostic, radiographic criteria for early-stage HCC have been defined (including nodules between 1 and 2 cm) and effective treatment is available for tumours detected at an early stage. Worldwide the approach to resection versus transplantation varies depending upon local resources, expertise and donor availability. The criteria for transplantation are discussed, and the controversial areas highlighted with evidence-based recommendations provided. Several approaches are available for intermediate stage disease, including radiofrequency ablation, transarterial chemoembolisation and radioembolisation; the rationale for these therapies is buttressed by appropriate outcome-based studies. For advanced disease, systemic therapy with sorafenib remains the option best supported by current data. Thus, while several trials have failed to improve the benefits of established therapies, studies assessing the sequential or combined application of those already known to be beneficial are needed. Also, new concepts are provided in regards to selecting and stratifying patients for second-line studies, which may help explain the failure of prior studies.",
author = "Jordi Bruix and Gores, {Gregory James} and Vincenzo Mazzaferro",
year = "2014",
month = "5",
day = "1",
doi = "10.1136/gutjnl-2013-306627",
language = "English (US)",
volume = "63",
pages = "844--855",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Hepatocellular carcinoma

T2 - Clinical frontiers and perspectives

AU - Bruix, Jordi

AU - Gores, Gregory James

AU - Mazzaferro, Vincenzo

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death and is currently the main event leading to death in patients with cirrhosis. Evolving information suggests that the metabolic syndrome with non-alcoholic liver disease may be an important cause of HCC in addition to viral hepatitis and alcohol-induced liver disease. The molecular pathogenesis is extremely complex and heterogeneous. To date the molecular information has not impacted on treatment decisions. Periodic surveillance imaging of patients with cirrhosis is widely practiced, especially because diagnostic, radiographic criteria for early-stage HCC have been defined (including nodules between 1 and 2 cm) and effective treatment is available for tumours detected at an early stage. Worldwide the approach to resection versus transplantation varies depending upon local resources, expertise and donor availability. The criteria for transplantation are discussed, and the controversial areas highlighted with evidence-based recommendations provided. Several approaches are available for intermediate stage disease, including radiofrequency ablation, transarterial chemoembolisation and radioembolisation; the rationale for these therapies is buttressed by appropriate outcome-based studies. For advanced disease, systemic therapy with sorafenib remains the option best supported by current data. Thus, while several trials have failed to improve the benefits of established therapies, studies assessing the sequential or combined application of those already known to be beneficial are needed. Also, new concepts are provided in regards to selecting and stratifying patients for second-line studies, which may help explain the failure of prior studies.

AB - Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death and is currently the main event leading to death in patients with cirrhosis. Evolving information suggests that the metabolic syndrome with non-alcoholic liver disease may be an important cause of HCC in addition to viral hepatitis and alcohol-induced liver disease. The molecular pathogenesis is extremely complex and heterogeneous. To date the molecular information has not impacted on treatment decisions. Periodic surveillance imaging of patients with cirrhosis is widely practiced, especially because diagnostic, radiographic criteria for early-stage HCC have been defined (including nodules between 1 and 2 cm) and effective treatment is available for tumours detected at an early stage. Worldwide the approach to resection versus transplantation varies depending upon local resources, expertise and donor availability. The criteria for transplantation are discussed, and the controversial areas highlighted with evidence-based recommendations provided. Several approaches are available for intermediate stage disease, including radiofrequency ablation, transarterial chemoembolisation and radioembolisation; the rationale for these therapies is buttressed by appropriate outcome-based studies. For advanced disease, systemic therapy with sorafenib remains the option best supported by current data. Thus, while several trials have failed to improve the benefits of established therapies, studies assessing the sequential or combined application of those already known to be beneficial are needed. Also, new concepts are provided in regards to selecting and stratifying patients for second-line studies, which may help explain the failure of prior studies.

UR - http://www.scopus.com/inward/record.url?scp=84898767802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898767802&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2013-306627

DO - 10.1136/gutjnl-2013-306627

M3 - Article

C2 - 24531850

AN - SCOPUS:84898767802

VL - 63

SP - 844

EP - 855

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -